 |
 |
| 5-Year Data |
|
|
See the results of the longest reported controlled clinical study of male pattern hair loss. |
|
|
| View study results. |
|
 |
 |
|
|
|
|
|
|
|
Licensed US physicians may request product samples online from Merck & Co., Inc., for distribution to patients. Samples can only be distributed upon receipt of a completed and mailed Sample Request Form from a licensed US physician.
To order product samples of PROPECIA® (finasteride), please visit MerckProductServices.com.
|
|
| Important Information About PROPECIA |
| |
 |
PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established. |
| |
|
PROPECIA is not indicated in women or children. |
| |
|
|
|
In clinical studies of 1 year for PROPECIA, each drug-related sexual adverse event occurred in less than 2% of men. Discontinuation due to drug-related sexual adverse experiences was 1.2% in the group treated with PROPECIA and 0.9% in the placebo-treated group. Reported drug-related sexual adverse experiences included decreased libido (1.8% vs 1.3%, placebo), erectile dysfunction (1.3% vs 0.7%, placebo), and ejaculation disorders (1.2% vs 0.7%, placebo), primarily decreased volume of ejaculate (0.8% vs 0.4%, placebo). Resolution occurred in the 1-year studies in men who discontinued therapy with PROPECIA due to these sexual side effects. The incidence of each of the above side effects decreased to <0.3% by the fifth year of treatment with PROPECIA. |
| |
|
In postmarketing experience, the following adverse events have been reported: breast tenderness and enlargement; hypersensitivity reactions including rash, pruritus, urticaria, and swelling of the lips and face; and testicular pain. |
|
|
|
|
